Thierry Facon
MD
Professor of Hematology
👥Biography 个人简介
Thierry Facon at CHU Lille led the FIRST trial establishing continuous lenalidomide-dexamethasone as a first-line option for transplant-ineligible myeloma, demonstrating superiority over the melphalan-based MPT regimen. He has been central to defining treatment for elderly and frail myeloma patients and has contributed to multiple French IFM cooperative group myeloma trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Thierry Facon 的研究动态
Follow Thierry Facon's research updates
留下邮箱，当我们发布与 Thierry Facon（CHU Lille）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment